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Objective: Endovascular therapy for moderate femoropopliteal arterial occlusive disease remains controversial. This study
reviewed our experience with endovascular therapy for TransAtlantic InterSociety Consensus (TASC) type B disease,
which is defined as multiple stenoses less than 3 cm in diameter or a single stenosis or occlusion 3 to 5 cm in diameter.
Stenosis-free patency was used as an objective end point to evaluate the hemodynamic outcome.
Methods: A retrospective review was performed of all patients who had undergone endovascular treatment of TASC type
B lesions between 1997 and 2002 at two referral centers. Balloon angioplasty was performed in all patients. Stenting was
used selectively as an adjunct in patients with suboptimal angioplasty results. The treated sites were examined with duplex
ultrasound scanning at 6-month to 12-month intervals. Stenosis-free patency was defined as the absence of stenosis
greater than 50% diameter in the treated arterial segment with standard duplex criteria.
Results: One hundred fifteen limbs in 98 patients were studied. The indication for treatment was claudication in 92
patients (80%) and ischemic rest pain or gangrene in the remaining patients (20%). Multiple lesions greater than 3 cm were
treated in 89 limbs (77%), and a single lesion 3 to 5 cm long was treated in 26 limbs (23%). Balloon angioplasty alone was
performed in 74 limbs (65%), and angioplasty and adjunctive stenting was performed in 41 limbs (35%). Endovascular
therapy was technically successful in all but one patient (99%), and there was no perioperative mortality or limb loss.
During follow-up recurrent stenosis was detected in 46 limbs (40%), and reocclusion occurred in 11 limbs (10%). Seven
patients (6%) underwent surgical bypass after endovascular treatment failure. The aggregate 1-year stenosis-free patency
rate at life table analysis was 55.1%. The 1-year stenosis-free patency for angioplasty alone was 58%, compared with 51%
(NS) for angioplasty and adjunctive stenting. Univariate regression analysis failed to demonstrate a difference in
stenosis-free patency for demographic variables, medical comorbidities, and anatomic characteristics (multiple vs single
lesions; number of angioplasty procedures).
Conclusions: Endovascular therapy for TASC type B femoropopliteal lesions is safe and technically feasible. However, the
length of time that a treated arterial segment remains free of stenosis is limited, and is not improved with adjunctive
stenting. Recurrent stenosis, not occlusion, was the most common study end point, and few patients subsequently
required surgical bypass. Predictors of outcome after endovascular therapy for TASC type B lesions were not identified
in this study. (J Vasc Surg 2004;39:343-50.)
Endovascular therapy for femoropopliteal arterial oc-
clusive disease offers several advantages over surgical by-
pass. It is less invasive and does not require an arterial
conduit, and patients recover quickly after treatment.
However, the durability of balloon angioplasty, with or
without stenting, in the femoropopliteal arterial segment
has not been equivalent to bypass in most reports. Recur-
rent stenosis rates as low as 10%1 and as high as 87%2 after
1 year have been reported. This wide range of reported
outcomes has made generalized recommendations for en-
dovascular treatment of femoropopliteal occlusive lesions
uncertain.
Differences in outcomes for endovascular treatment
may be related to differences in the anatomy of lesions
treated, and few studies have stratified patients on the basis
of severity of the femoropopliteal lesion. In 2000 the
TransAtlantic Inter-Society Consensus (TASC) catego-
rized femoropopliteal arterial occlusive disease into four
groups according to lesion anatomy.3 Definitions of each
category are shown in Table I. Based on previously pub-
lished results, the TASC working group supported endo-
vascular therapy for short focal stenoses classified as TASC
type A lesions, and surgical bypass for complete, long
occlusions classified as TASC type D lesions. A lack of
supporting evidence prevented the TASC authors from
reaching a consensus on guidelines for treating TASC type
B and type C lesions.
The purpose of this study was to examine endovascular
treatment of TASC type B femoropopliteal occlusive le-
sions. Duplex ultrasound scanning was used to determine
stenosis-free patency in each treated arterial segment,
which served as the primary outcome measure. Stenosis-
free patency may be a more relevant and quantifiable out-
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come measure than anatomic patency or clinical response.
Duplex scans of extremity arteries can objectively demon-
strate the presence of recurrent stenosis in a treated seg-
ment, and early recurrent stenosis is known to compromise
the late outcomes of virtually all endovascular treatments.
METHODS
Data for all patients undergoing femoropopliteal an-
gioplasty between January 1997 and December 2002 at
two referral medical centers were reviewed. Arteriographic
images identified limbs treated for TASC type B disease,
which was defined as a single stenosis or occlusion 3 to 5 cm
long or multiple stenoses or occlusions less than 3 cm long.
Patients who had undergone previous endovascular treat-
ments or surgical bypass in the affected limb were excluded.
This study was approved by the Institutional Review Board
of the University of Maryland School of Medicine.
The indication for treatment was classified according to
the revised version of the Joint Council of the Society for
Vascular Surgery and the North American Chapter of the
International Society for Cardiovascular Surgery (SVS/
ISCVS) scale for chronic limb ischemia.4 Preoperative an-
kle-brachial index (ABI) was recorded in all cases. A com-
bination of duplex ultrasound scanning, preoperative
angiography, and intraoperative angiography was used to
select patients for possible intervention. Patients who re-
quired bilateral interventions underwent staged interven-
tions at least 4 days apart.
Vascular surgeons performed all procedures in an op-
erating suite with mobile fluoroscopy. Selective, intraoper-
ative angiography of the affected limb was performed, and
after administration of heparin (3000-5000 units), a 0.035-
inch wire was advanced through the occlusive lesions.
Balloon angioplasty was performed primarily, and dilated
lesions were evaluated at repeat angiography. Stenting was
performed selectively in patients with suboptimal angio-
plasty results, including flow-limiting arterial dissection or
greater than 30% residual stenosis.
All patients received aspirin therapy postoperatively
(325 mg/d), and those who required stenting received
clopidogrel (75 mg/d) for 1 month. Clinical status post-
operatively was assessed with the SVS/ISCVS scale. The
scale assigns a score of 3 for markedly improved symp-
toms combined with ABI greater than 0.90; 2 for im-
provement of at least a single chronic limb ischemia cate-
gory combined with ABI increase greater than 0.10;1 for
either a single category improvement or an increase in ABI
greater than 0.10; 0 for unchanged symptoms; and 1 to
3 for deterioration of symptoms and ABI. Patients were
not instructed to follow any specific program of exercise
after endovascular intervention.
Duplex scanning of the treated arterial segment was
performed 1, 6, and 12 months postoperatively, and then
annually. Stenosis-free patency was defined as the absence
of stenosis greater than 50% in diameter in the treated
arterial segment. Criteria for detection of recurrent stenosis
was a focal greater than 50% increase in peak systolic
velocity compared with the normal adjacent segment, with
associated turbulence and peak systolic velocity ratio of the
stenotic area to the adjacent normal artery exceeding 2.5.5
These criteria were based on previously established duplex
standards for the evaluation of vein bypass graft stenosis. A
formal comparison of these duplex critieria with angio-
graphic images after endovascular therapy has not been
performed. However, angiography was performed in 23
patients with recurrent stenosis detected at duplex scan-
ning, and the angiographic images confirmed the duplex
scanning findings in all 23 cases.
When a secondary endovascular procedure was re-
quired to restore stenosis-free patency, it was recorded as
“secondary stenosis-free patency.” Anatomic patency was
defined as the detection of any flow within the treated
arterial segment at ultrasonography.
Kaplan-Meier life table analysis was used to assess ste-
nosis-free patency, secondary stenosis-free patency, and
anatomic patency for all variables. Log rank univariate
analysis was performed to compare stenosis-free patency for
Table II. Demographic and clinical characteristics
n %
No. of patients 98
Gender
Male 48
Female 50
Age (y)
Mean 68
Range 36-89
Diabetes 44 46
Tobacco use 59 61
Hypertension 79 82
Hyperlipidemia 65 68
Treatment Indication: SVS/ISCVS chronic limb ischemia grade
(n  115 limbs)
I: Claudication 92 80
II: Rest pain 8 7
III: Gangrene 15 13
SVS, Society for Vascular Surgery; ISCVS, International Society for Cardio-
vascular Surgery.
Table I. TASC morphologic stratification of
femoropopliteal lesions
TASC type A Single stenosis up to 3 cm long, not at origin
of superficial femoral artery or distal
popliteal artery
TASC type B Single stenosis or occlusion 3-5 cm long, not
involving distal popliteal artery
Multiple stenoses or occlusions, each less than
3 cm long
TASC type C Single stenosis or occlusion longer than 5 cm
Multiple stenoses or occlusions, each 3-5 cm
long
TASC type D Complete common femoral artery or
superficial artery occlusions or complete
popliteal and proximal trifurcation
occlusions
TASC, TransAtlantic Intersociety Consensus document.
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any given variable. Calculations were performed with Stat-
view software (SAS Institute, Cary, NC).
RESULTS
One hundred fifteen limbs in 98 patients were treated
with endovascular therapy for TASC type B femoropopli-
teal occlusive lesions. Patient characteristics are shown in
Table II. The treatment indication was claudication in 92
limbs (80%), rest pain in 8 limbs (7%), and gangrene in 15
limbs (13%). Lesion characteristics and types of treatment
are shown in Table III.
Percutaneous, antegrade cannulation of the ipsiplateral
common femoral artery was performed in 83 limbs (72%),
and direct surgical exposure of the femoral artery was used
in the remaining 32 limbs. Balloon angioplasty was per-
formed a mean of 2.2 times (range, 1-4 times) per limb.
Mean balloon diameter was 5.8 mm (range, 3-6 mm).
Stents were placed in 41 limbs (35%); balloon-expandable
stents (Palmaz; Cordis Johnson & Johnson) were used in
28 limbs (68%), and self-expanding stents (Wallstent; Bos-
ton Scientific, Natick, Mass) in 13 (32%) limbs. The indi-
cation for stenting was residual stenosis in 36 limbs (87%)
and flow-limiting dissection in 5 limbs (13%).
Wire access and balloon angioplasty was accomplished
in all cases. Occlusion of the treated arterial segment in the
first 24 hours occurred in one limb, for an initial technical
success rate of 99% in this series. This patient required
below-knee amputation after unsuccessful surgical bypass.
There were four periprocedural complications (3.5%); two
groin hematomas, one of which required operative evacu-
ation; one pseudoaneurysm; and one deep venous throm-
bosis. In the first 30 days after the procedure, occlusion or
recurrent stenosis of the treated arterial segment occurred
in 10 (8.7%) limbs (occlusion, 3 limbs; recurrent stenosis, 7
limbs). Three patients (2.6%) required surgical intervention
after endovascular treatment failure in the first 30 days. The
initial treatment indication in all three patients was rest
pain. No patients in this series died within 30 days of the
procedure.
The mean ABI in treated limbs increased from 0.61
(SD, 0.21) to 0.84 (SD, 0.23) post-procedure (P. 0001).
The post-procedure clinical status score was2 or3 in 76
limbs (66%), 1 or higher in 30 limbs (26%), 0 (un-
changed) in 8 limbs (7.1%), and 1 in 1 limb (0.8%). No
difference in clinical status score was noted in patients
treated with angioplasty alone versus angioplasty and stent-
ing. A score of 2 or 3 was assigned to 66% of limbs
treated with angioplasty alone, versus 65% of limbs treated
with balloon angioplasty and stenting. The single patient
with deterioration in clinical status was treated with balloon
angioplasty of three stenotic areas of the superficial femoral
artery, one of which required a Palmaz stent. ABI decreased
from 0.53 preoperatively to 0.40 postoperatively, and du-
plex ultrasound scans 4 days post-procedure showed occlu-
sion of the superficial femoral artery. The patient subse-
quently underwent elective femoropopliteal bypass.
Mean follow-up for the study group was 16.9 months
(range, 1-66 months; median, 10 months). Follow-up was
incomplete in 28 patients (24%). Stenosis-free patency at
life table analysis at 6, 12, and 24 months was 61.0%,
55.1%, and 44.0%, respectively (Fig 1; Table IV), and
anatomic patency (SE) was 90.3% (3.1), 88.6% (3.5), and
84.3% (5.3), respectively. Stenosis-free patency for limbs
treated with adjunctive stenting was 65.4% (7.8), 51.8%
(8.3), and 39.5% (9.8), respectively, at 6, 12, and 24
months, compared with 59.5% (6.5), 59.5% (6.5), and
46.6% (9.1), respectively, for balloon angioplasty alone
(Fig 2). Log rank analysis did not demonstrate any signifi-
cant difference between stenosis-free patency rate for
stented limbs versus limbs treated with angioplasty alone (P
 .73). Proportional hazards and univariate regression
analysis did not identify any differences in stenosis-free
patency for any demographic (age, gender), clinical (diabe-
tes, tobacco use, treatment indication), or anatomic (mul-
tiple vs single lesions; number of angioplasties) variables
evaluated.
At follow-up recurrent stenosis or occlusion of the
treated femoropopliteal arterial segment was detected in 57
limbs (50%) limbs (Table V). Femoropopliteal occlusion
was observed in 11 limbs (19%), but recurrent stenosis
caused most (81%) treatment failures. Sixteen limbs (28%)
underwent secondary endovascular treatments, which re-
sulted in a secondary stenosis-free patency rate of 68.3%,
Table IV. Cumulative life table analysis: Primary
stenosis-free patency
Interval
(mo)
No. at
risk
No.
failed
No.
withdrawn*
Cumulative
patency (%) SE (%)
Entry 115 0 0 100 0
3 78 13 24 75.5 5.4
6 59 3 16 61.0 7.8
12 31 22 6 55.1 9.0
18 22 9 0 55.1 9.0
24 15 3 4 44.0 14.5
*Number of patients withdrawn because of death or loss to follow-up.
Table III. Femoropopliteal lesion characteristics and
treatment
Limbs
n %
Lesion type
Single 3-5 cm 26 23
Multiple  3cm 89 77
Lesion location
Superficial femoral artery 30 26.7
Popliteal 5 4.3
Superficial femoral and
popliteal arteries
80 69
Treatment
Balloon angioplasty alone 74 65
Angioplasty and stent 41 35
Balloon-expandable stent 28 68
Self-expanding stent 13 32
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60.1%, and 51.6% at 6, 12, and 24 months respectively (Fig
1; Table VI). Seven patients (12%) required surgical bypass
after failure of endovascular therapy. The remaining 34
limbs with treatment failure did not undergo repeat inter-
vention during the study.
The mean ABI at the time of most recent follow-up in
all patients was 0.72 (SD, 0.25). Limbs in which recurrent
stenosis was detected in the treated arterial segment had a
mean follow-up ABI of 0.62 (SD, 0.25), which was signif-
icantly lower than the mean ABI of 0.81 (SD, 0.21) re-
corded in limbs that were patent and free of stenosis (P 
.001). Clinical status score during follow-up correlated
weakly with follow-up ABI (Pearson correlation coefficient,
.675). In the 57 limbs with recurrent stenosis, clinical status
score decreased in 34 cases (60%) and remained unchanged
in 23 cases (40%). In the 58 limbs that achieved stenosis-
free patency, clinical status score decreased in 13 cases
(22%) and remained unchanged in 45 cases (78%).
Below-knee amputation was performed after treatment
failure in two patients (2%). One patient with occlusion of
the treated superficial femoral artery lesions in the first 24
hours after balloon angioplasty was previously described.
The other patient underwent amputation when endovascu-
lar treatment for ischemic ulceration failed 4 months after
the procedure. Six patients (5.2%) had toe amputations.
The treatment indication for these patients was ischemic
ulceration in three, rest pain in two, and claudication in
one. The one patient with claudication underwent a toe
amputation 5 years after endovascular intervention.
DISCUSSION
The TASC authors failed to reach a consensus on
endovascular therapy for TASC type B femoropopliteal
lesions, and identified this topic as a “critical issue” that
required more data.3 The purpose of this study was to
examine the results of balloon angioplasty and selective
stenting for TASC type B femoropopliteal occlusive lesions.
Although several reports of endovascular treatment for
femoropopliteal disease exist,6-8 few studies have focused
on a single TASC category and used an objective measure-
ment of hemodynamic response to treatment.
Balloon angioplasty and stenting of TASC type B fem-
oropopliteal occlusive lesions proved safe and technically
feasible. Although nearly all patients had multiple athero-
sclerotic risk factors, there were no perioperative deaths,
and few complications (3.5%). Similar to previous re-
ports,9-11 the current study had a very low rate (1%) of
technical failure. All lesions in this series were crossed with
a wire, which is consistent with the experience of Karch et
al,12 who noted only one wire access failure in 112 lesions.
Selective stenting contributed to the high initial success
rate by achieving morphologic success in all 41 limbs that
had a suboptimal response to balloon angioplasty alone.
Failure to address residual stenosis or flow-limiting dissec-
tion after balloon angioplasty may increase the risk for
endovascular treatment failure.13,14 The proportion of pa-
tients (35%) requiring selective stenting in our series was
higher than the 15% rate reported by Becquemin et al.15
The reason for this difference in selective stenting rates may
be related to the number of stenotic lesions per limb that
required balloon angioplasty. In our series 77% of limbs had
multiple stenotic lesions, and balloon angioplasty was per-
formed a mean of 2.2 times per limb. In contrast, Becque-
min et al15 treated a single lesion in all cases, and although
they did not specify the mean lesion length, the mean
length of the angioplasty balloon used was 3.75 cm.
Despite achieving initial morphologic success, stent
placement did not result in a sustained increase in stenosis-
free patency compared with balloon angioplasty alone.
These results support the findings of Becquemin et al,10
who reported equivalent 1-year stenosis-free patency rates
(66% and 68%) for patients randomized to receive system-
atic versus selective stenting. Their study questioned the
effect of the stent itself on the treated arterial lesion. These
authors used Palmaz stents exclusively, and found that the
Fig 2. Cumulative life table analysis for stenosis-free patency of
balloon angioplasty alone and balloon angioplasty and adjunctive
stenting.
Fig 1. Cumulative life table analysis for primary and secondary
stenosis-free patency.
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115 patients randomized to receive systematic stenting
experienced 31 more vascular events on the treated limb
than the selective stenting group. Our study used Palmaz
stents in 28 of 41 cases (68%), and after 6 months the
stented limbs showed a trend toward decreased stenosis-
free patency compared with limbs that underwent balloon
angioplasty alone. This lack of sustained success after stent-
ing raises speculation that Palmaz stenting could have a
deleterious effect on femoropopliteal occlusive lesions.
Recent studies of technical and therapeutic innovations
in stent design have yielded promising short-term results in
the treatment of femoropopliteal occlusive lesions. Jahnke
et al16 reported a 12-month patency rate of 86% in 37
patients in whom nitinol self-expanding stents were placed
to treat short (3 cm) superficial femoral artery lesions. In
a prospective randomized study, Saxon et al17 noted a
6-month patency rate of 93% in patients treated with ex-
pandable polytetrafluoroethylene–covered stent grafts,
versus 42% for patients randomized to balloon angioplasty
alone. Duda et al18 showed that after 6 months in the
superficial femoral artery the in-stent mean diameter of
sirolimus-eluting nitinol stents was 0.64 mm larger than
the in-stent diameter of noneluting stents (mean lesion
length, 8.5 cm). These advances in stent design may be
necessary for stents to offer both improved morphologic
success and superior sustained patency. Future studies with
new stents may achieve superior results to those reported in
this study, in which we used only Palmaz stents and Wall-
stents.
Although endovascular therapy resulted in immediate
clinical improvement in 90% of treated limbs in our series,
follow-up surveillance showed that stenosis-free patency
decreased to 55.4% at 1 year and 44.2% at 2 years. Clark et
al19 reported data from an endovascular registry compiled
by interventional radiologists to claim patency rates for
femoropopliteal angioplasty of 87%, 80%, and 55% at 1, 2,
and 5 years, respectively. The reason their patency results
appear to be superior to ours may derive from the different
methods used for hemodynamic assessment. Clark and
colleagues defined patency as the absence of deterioration
in clinical category and an ABI within 0.15 of the post-
angioplasty level. In a patient population dominated by
those with claudication, resting arterial perfusion appears to
be an inadequate method for determining the treatment
response to endovascular therapy. An evolving greater than
50% stenosis after angioplasty is unlikely to translate into a
significant decrease in resting ABI, and would therefore go
undetected with the surveillance method used by Clark et
al.19 However, this type of recurrent stenotic lesion after
angioplasty results in predictable treatment failure. Detect-
ing these recurrent stenotic lesions requires objective im-
aging, and in contrast to our study, Clark and colleagues
did not follow up patients with ultrasound scanning.
The ideal method for determining treatment success or
failure after endovascular therapy remains elusive. Angiog-
raphy provides an anatomic rather than hemodynamic eval-
uation, and is not well-suited for serial surveillance. This
study used stenosis-free patency, as determined with duplex
ultrasound scanning, as the primary outcome measure, and
assumed that hemodynamic success after angioplasty and
stenting correlated with treatment success. Karch et al6
question this assumption, and assert that anatomic patency
can coexist with treatment failure. In their study of 45
clinical failures after femoropopliteal angioplasty, 40% of
the failures occurred despite anatomic patency of the
treated arterial segment. In our study, 13 patients had a
decrease in clinical status score despite documented steno-
sis-free patency of the treated arterial segment. Karch et al6
stressed the need to include both anatomic and clinical
measures of success in studies of endovascular therapy.
Although stenosis-free patency, ABI, and clinical status
score were recorded in this study, none of these variables
provided a consistent and accurate measure of treatment
success. Inasmuch as patients with claudication make up a
Table V. Management of treatment failure
Treatment failure
(n  57)
Limbs Endovascular
repeat
intervention
Surgical
bypass Observationn %
Recurrent stenosis 46 40 13 0 33
Occlusion 11 10 3 7 1
Table VI. Cumulative life table analysis: Secondary stenosis-free patency
Interval (mo) No. at risk No. failed
No.
withdrawn*
Cumulative
patency (%) SE (%)
Entry 115 0 0 100 0
3 82 13 20 78.9 4.9
6 63 6 13 68.3 6.7
12 34 22 7 60.1 8.6
18 23 11 0 60.1 8.6
24 17 3 3 51.6 12.4
*Number of patients withdrawn because of death or loss to follow-up.
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large portion of patients treated for TASC type B lesions,
accurate evaluation of treatment success or failure may
require physiologic assessment in the form of treadmill
testing.
The presence of multiple lesions in 77% of treated limbs
can also explain why our patency rates appear to be lower
than those of other reported series. Treatment of a greater
number of lesions in the femoropopliteal arterial segment
increases the number of sites at risk for recurrent stenosis.
Therefore, if recurrent stenosis develops at just one of these
sites, the entire limb is classified as a treatment failure,
according to the end points defined in our study. Further
support for this observation was present in the series by
Clark et al.11 Only 28% of the limbs in their series had
multiple lesions, and univariate analysis showed that angio-
plasty of more than one lesion was associated with de-
creased patency rates.
The sharp decline in stenosis-free patency in this report
is similar to the findings of Jamesen et al.20 These authors
reported a 12-month primary patency rate of 46% after 218
femoropopliteal angioplasty procedures in 173 patients
with claudication. Long-term follow-up showed a more
gradual decline in patency, to 25% at 5 years and 14% at 10
years. Although Jamesen et al20 did not use the TASC
classification, they appear to have treated slightly more
severe femoropopliteal occlusive disease than TASC type B
lesions. The average total length of treated lesions per limb
in their report was 8.8 cm, and the average length of an
individual lesion was 5.2 cm. The authors concluded that
femoropopliteal angioplasty was a reasonable treatment
option for claudication, despite its limited durability. In
their series, only 32% of limbs treated required repeat
interventions, and half of these were amenable to repeat
endovascular therapy, whereas the others required surgical
bypass. In our series, 20% of limbs treated required repeat
interventions, and more than two thirds were amenable to
repeat endovascular therapy. The number of limbs requir-
ing surgical intervention after angioplasty failure in our
series (13%) and in the series by Jamesen et al20 (16%) was
similar to the surgical repeat intervention rate (17.8%) after
bypass surgery in a similar cohort of patients with claudica-
tion.21
The use of femoropopliteal angioplasty and stenting to
treat claudication remains a controversial issue. A definitive
answer to this question would require a prospective ran-
domized study that included a control group, as well as
endovascular and medical therapy groups. Hunink et al22
used decision and cost-effectiveness analysis to assert that
angioplasty is the preferred initial treatment in patients with
disabling claudication, as long as the 5-year patency rate for
angioplasty exceeded 30%. The current study lacks long-
term results, and cannot be used to support angioplasty to
treat claudication, according to the model by Hunink et
al.22 However, endovascular therapy for patients with clau-
dication with TASC type B lesions does achieve acceptable
intermediate results. Clinical improvement was achieved in
92% of patients with claudication. None of these patients
had acute clinical deterioration, and only one patient with
claudiction required a toe amputation, 5 years after angio-
plasty. Femoropopliteal occlusions occurred in six patients
treated for claudication (6.7%), and only two (2.2%) of
these patients required surgical bypass.
The small number of patients and the inhomogeneous
patient population in this study may explain its failure to
identify predictors of outcome after angioplasty. Because all
patients with TASC type B lesions were studied, patients
with rest pain (8%) and gangrene (12%) were included and
grouped with patients with claudication. Angioplasty and
stenting may have lower success rates when performed in
patients with critical limb ischemia. Lofberg et al23 found a
1-year primary success rate of 47% for patients with TASC
type B–comparable lesions who were being treated for rest
pain or gangrene. In a similar study in patients with isch-
emic ulcers, Mlekusch et al24 reported a 1-year stenosis-free
patency rate of 48%. Clarifying the role of endovascular
therapy in the treatment of femoropopliteal disease may
require that future studies stratify patients by both lesion
anatomy and treatment indications.
In conclusion, endovascular therapy appears to be a
reasonable treatement option for TASC type B femoropop-
liteal occlusive lesions. In our series endovascular therapy
proved a technically feasible and safe treatment, and
achieved clinical improvement in most patients. Recurrent
stenosis, not reocclusion, was the most common study end
point, and very few patients subsequently required surgical
revascularization. Although treatment durability was lim-
ited, a group of patients did achieve documented stenosis-
free patency for more than 2 years. Outcome predictors for
TASC type B lesions treated with endovascular therapy
were not identified in this study.
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DISCUSSION
Dr Sachinder S. Hans (Warren, Mich). I think, as you
yourself admitted, your numbers are really small. If you really look
at the literature from radiology from early ’90s, I think in a patient
with claudication who is diabetic and has multiple areas of super-
ficial femoral artery stenosis, I do not think it’s worthwhile to even
attempt this procedure. This procedure is probably useful for a
localized stenosis in a nondiabetic patient.
Dr Michael J. Costanza. I agree. In the published series from
radiology groups, patients with multiple lesions have significantly
inferior results compared with patients with single lesions, even by
the radiologists’ definition of patency, which is much less rigorous
than the definition we used.
Dr Darius G. Azin(Bend, Ore). Your conclusion is that
endovascular therapy is safe and technically feasible for type B
lesions. Can you tell me about the outcome of the patients in
whom the therapy failed? In other words, were they left off worse
than they were before you intervened?
Dr Costanza. There were two surgical bypasses performed in
claudicants after failed endovascular therapy. There were six other
bypasses done, in patients who were all being treated for critical
limb ischemia. There was one toe amputation in a claudicant,
which was done 5 years after endovascular intervention. So I would
have to conclude that the vast majority of patients were not worse
off after endovascular therapy.
Dr George Andros (Encino, Calif). I’d like to ask you a few
questions.
Did you stratify the patients traditionally, as is done with
runoff vessels?
Second, did you ever just total up the number of stenotic
lesions? With those chain-of-lakes lesions that you showed us, do
you stop at three, four, or five? Do you have any guidelines?
Third, do you ever use intraoperative duplex to see how well
you’ve done? Because they all look pretty ugly when you’re fin-
ished with the angioplasty.
And along those lines, how do you decide when to stent? Do
you apply some objective criteria?
And one final question: whatever happened to so-called med-
ical therapy?
Dr Costanza. We did try to stratify the runoff according to
the standard published scales, but our sample size was too small to
show differences between runoff score groups.
It was difficult to quantify the number of lesions per limb,
because several lesions were often treated with one long balloon
angioplasty. We did examine the effect of the number of balloon
angioplasties per limb, but again that did not show any significant
differences.
We did not use intraoperative duplex to assess success. Our
criteria for stenting were residual stenosis of greater than 30% or
flow-limiting dissection.
And in terms of medical therapy, many of these patients had
had medical therapy, and were not satisfied. But again, this study
was not designed to look at the success or failure of medical therapy
compared with endovascular therapy.
Dr Mark A. Mattos (Seattle, Wash). Dr. Costanza, that was a
very nice paper, but I think you need to rename it. You didn’t really
look at any hemodynamic objectives, but it is simply an anatomic
evaluation of your patients after ballooning and stenting of the
SFA.
Second, in the year 2003 it’s probably not appropriate to talk
only about anatomic success or failure in endovascular therapy. I
think you need to look at all aspects— clinical, hemodynamic, and
anatomic success or failure—and then combine the groups, as
suggested by the reporting standards in 1996 led by Dr. Ahn. I
would encourage you to go back and relook at your data, look at it
in multiple ways, look at vessel diameter and its effect on stenting
in the SFA, which we believe is very important, and then come back
and resubmit the data in another year and see what we have.
Dr Costanza. This study looked specifically at the hemody-
namic response by evaluating the treated arterial segment for
restenosis. It was motivated in part as a response to many of the
radiology papers that have just looked at anatomic patency or the
presence of arterial flow, and not looked for the development of
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restenosis. We believe that restenosis is a very important outcome,
especially when treating claudicants.
I agree one of the weaknesses of the study is that we did not
use clinical indicators of intermediate and long-term success. The
study could be improved by including clinical criteria and treadmill
testing, to bring out some of the changes in perfusion that would
be missed by relying on resting ABIs.
Dr Munier Nazzal (Toledo, Ohio). Actually, our experience
with that is a little bit different from what was mentioned. We use
angioplasty and stenting liberally in certain SFA lesions.
Did you look at the type of stent you used? Yours from 1996,
when Wallstent was used mostly, now are hardly used.
The other thing: did you look at medical therapy around the
time you used the stent, like Plavix or aspirin, because it is so
important to put those patients on medical therapy around the
time of angioplasty.
Dr Costanza. Two thirds of our stents were Palmaz, balloon-
expandable, and the remaining were Wallstents. So I agree that
these results may have been vastly different had the newer stent
technologies been used.
All of the patients were on aspirin. And 90% of the patients
who received stents were maintained on Plavix for 1 month post-
operatively.
Dr Peter J. Schubart (San Jose, Calif). I noticed that you had
a fairly high rate of stenting for TASC B lesions. That raises the
question of how you defined suboptimal angioplasty.
Second, since the majority of the patients were treated for
claudication, and you showed that they had an improvement in
their clinical status, was there any correlation between the devel-
opment of restenosis and change in their clinical status subse-
quently?
Dr Costanza. The criteria we used for stenting were greater
than 30% residual stenosis or flow-limiting dissection. I agree that
our stent rate is higher than several reported series of selective
stenting, and I think that is related to our inclusion of many more
patients with multiple lesions, whereas the other series had a very
small number of patients with multiple lesions or none at all.
In terms of the clinical follow-up, we do not have that as part
of this study, and that would be an addition that would be helpful.
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